SEC Filing Summary: Stratus Media Group, Inc. Form 10-Q
Period: Quarter ended September 30, 2013; filed November 19, 2013. The request metadata names Cervomed Inc., but the filing identifies Stratus Media Group, Inc. as the registrant.
Business context and reporting period
Stratus had suspended development of its prior event businesses and, in June 2013, suspended its ProElite mixed martial arts business. It reported minimal residual licensing revenue and was seeking capital and acquisitions. On September 30, it agreed to acquire Canterbury Laboratories and Hygeia Therapeutics, developers of cosmeceutical products; the acquisition closed November 18, 2013, subject to rescission if the company failed to raise at least $7.5 million by January 15, 2014.
Financial results and liquidity
| Metric | Q3 2013 | Q3 2012, restated | Nine months 2013 | Nine months 2012, restated |
|---|---|---|---|---|
| Revenue | $0 | $143,334 | $71,667 | $374,542 |
| Operating expenses | $1,555,152 | $3,568,734 | $12,045,616 | $8,359,830 |
| Operating loss | $1,555,152 | $3,426,250 | $11,973,949 | $8,221,091 |
| Net loss | $1,538,911 | $1,322,003 | $1,682,632 | $22,797,656 |
| Net loss attributable to common shareholders | $1,525,277 | $1,441,831 | $1,826,192 | $23,157,122 |
| Basic and diluted loss per share | $0.00 | $0.02 | $0.01 | $0.26 |
The filing presents losses per share in parentheses; amounts above show the loss magnitude. Q3 gross profit was zero; nine-month gross profit was $71,667, with no cost of revenue reported for that period’s licensing revenue. Operating expenses included a $1,935,621 goodwill impairment for ProElite in the nine-month period and substantial stock, option and warrant charges. A $10,389,607 gain from derivative-liability revaluation and extinguishment substantially reduced the reported nine-month net loss; it was not operating revenue.
At September 30, cash was $255,596, total assets $3,234,508, current liabilities $9,570,679, and shareholders’ deficit $6,336,171. Negative working capital was $6,361,637. Current assets included $2,901,438 in prepaid expenses and deposits, mostly unamortized shares issued for a three-year financial advisory agreement. Notes payable totaled $2,575,002, including $1,825,002 of promissory notes reported in default. The company also had $1,425,365 of deferred salary and $1,260,644 of rent liabilities.
For the first nine months, operating activities used $1,183,997 of cash; financing provided $1,127,500, comprising $700,000 of notes and $427,500 from common-stock sales. Cash declined $56,497, from $312,093 to $255,596. Cash paid for interest and income taxes was reported as zero.
Material changes versus comparable periods
- Revenue fell to zero in Q3 and to $71,667 for nine months, versus $143,334 and $374,542, respectively. The last Strikeforce licensing payment was received in January 2013, and the filing says no further such payments were expected.
- Q3 operating expenses declined 56% year over year, mainly due to lower staffing and other cost reductions. Nine-month operating expenses increased, principally reflecting the ProElite goodwill impairment, stock-based compensation and a $3,069,792 charge for common shares exchanged for warrants.
- Nine-month net loss was substantially lower than in 2012, largely because 2013 recorded derivative-related gains, whereas 2012 included a large derivative fair-value expense. These noncash, valuation-sensitive items make headline loss comparisons less indicative of underlying operations.
- Common shares outstanding rose from 89,083,677 at December 31, 2012 to 420,966,252 at September 30, 2013, through preferred-stock and warrant exchanges, debt conversions, advisory shares and stock sales. The filing reports 441,949,585 shares outstanding on November 19.
- The 2012 comparative financial statements were restated for derivative accounting. For the nine months ended September 30, 2012, restated loss attributable to common shareholders was $23,157,122 versus $9,317,865 previously reported.
Outlook, risks, contingencies and unusual items
- Going concern: Management stated that additional capital was needed to meet obligations and that, without financing, the company might not continue as a going concern. The filing cites recurring losses, negative working capital and defaulted notes. Management planned to seek $10 million or more, but provided no assurance financing would be available on acceptable terms or at all.
- Acquisition and financing condition: Canterbury and Hygeia were acquired for 115,011,563 restricted shares. The transaction may be rescinded if at least $7.5 million in gross financing proceeds is not raised by January 15, 2014. The company estimated the shares’ value at $4,933,996 at closing; the independent valuation and allocation to the Yale intellectual-property license were not finalized.
- Creditor settlement and dilution: A court order related to $1,865,386 of creditor and employee liabilities is to be settled with tradable common shares. Share count and expense may increase if the stock price falls; the filing warns that selling by the financial firm could pressure the stock price. It reported an initial 20 million-share tranche issued November 15, 2013.
- Other contingencies: The company accrued $393,592 for a property-damage claim, while disputing responsibility and insurance coverage. It also reported unresolved claims and obligations involving former offices, including rent liabilities, and noted negotiations to settle some amounts.
- Equity structure: A 1-for-50 to 1-for-100 reverse split had been proposed after the period; the board was to determine the ratio. The filing also describes substantial potential further share issuance for financing and acquisitions.
- Controls: Management concluded that disclosure controls were ineffective, citing lack of segregation of duties, insufficient written procedures for contracts and commitments, and inadequate accounting-software oversight. No material changes to internal control over financial reporting were reported during the quarter.
- Management outlook: Stratus said it intended to pursue acquisitions subject to sufficient capital. A proposed Histogen acquisition was abandoned. No specific operating or revenue guidance was provided.
Important facts for investors to verify
- Whether the company raised the required acquisition financing by January 15, 2014, and whether the Canterbury/Hygeia merger remained effective.
- The final independent valuation and accounting treatment of the Yale license and acquired businesses.
- Cash runway, current liquidity, status of defaulted notes, and actual completion and accounting of creditor settlements.
- Fully diluted share count after the merger consideration, creditor-settlement shares, planned financing and proposed reverse split.
- Resolution of the property-damage and former-office lease matters, and any changes to the company’s going-concern assessment or ineffective controls.